MedPath

Primary Irritation Patch Testing on Adult Healthy Human Subjects with Sensitive Skin. (Single 24-Hour Application)

Not Applicable
Completed
Registration Number
CTRI/2022/11/046975
Lead Sponsor
ITC Life Sciences Technology Centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
38
Inclusion Criteria

1)Subjects with Fitzpatrick skin type III to V

2)Sex: Males and non-pregnant/non-lactating females (preferably equal numbers of males and females).

3)Subjects scoring greater than 30 for Section 2- Sensitive v/s Resistant skin in modified Dr. Baumannâ??s skin type questionnaire.

4)Subjects identified to have sensitive skin on the basis of Dermatological assessment of skin with fine texture and closeness of blood vessels to the surface.

Exclusion Criteria

1)Subjects who are pregnant or nursing (as confirmed by Urine Pregnancy Test for the determination of Pregnancy).

2)Subjects under chronic medication (e.g. Antihistamines, Antifungals, Corticosteroids, topical Steroids, etc.) that might influence the outcome of the study.

3)Subjects with cutaneous disease, chronic illness or self-reported Immunological disorders or any other illness including Diabetes, liver disease, HIV or any other serious medical illness.

4)Subject suffering from any active clinically significant skin diseases which may contraindicate.

5)Subjects with known allergy or sensitization to medical adhesives, bandages or a present condition of allergic response to any cosmetic product.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Irritation Potential of test productsTimepoint: 24 hours post patch removal (Day 03)
Secondary Outcome Measures
NameTimeMethod
Irritation Potential of test productsTimepoint: 30 minutes post patch removal (Day 02) and 168 hours post patch removal (Day 09);Irritation potential of the test products by Subject Self-assessment (Irritation)Timepoint: Day 01, Day 02, Day 03 & Day 09;Safety by asking well-being of subject and Adverse Event assessmentTimepoint: Day 02, Day 03 & Day 09
© Copyright 2025. All Rights Reserved by MedPath